Ipilimumab-induced colitis on FDG PET/CT

Clinical Nuclear Medicine

Volumn 37, Issue 6, 2012, Pages 629-630

  Lyall, Ashima ^a   Vargas, Herbert Alberto ^a   Carvajal, Richard D ^a   Ulaner, Gary ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

colitis; FDG; ipilimumab

Indexed keywords

FLUORODEOXYGLUCOSE; IPILIMUMAB; STEROID;

ADULT; ARTICLE; CASE REPORT; CHILL; COLITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DRUG INDUCED DISEASE; FEMALE; HUMAN; MELANOMA; MULTIPLE CYCLE TREATMENT; SIDE EFFECT; SWEATING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLITIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84861442744     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318248549a     Document Type: Article

References (10)

1. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-618. (Pubitemid 34752469)
2. Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol. 2010;37:440-449.
3. Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58:1297-1306.
4. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-833.
5. Yang JC, Hughes H, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830. (Pubitemid 350295361)
6. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.
7. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti- CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507.
8. Goethals L, Wilgenhof S, De Geeter F, et al. (18)F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis. Eur J Nucl Med Mol Imaging. 2011;38:1390-1391.
9. Gupta A, Smith J, Scholes J, et al. An unusual case of colitis: drug induced inflammatory bowel disease. Am J Gastroenterol. 2008;103:S347.
10. Grob J, Hamid O, Wolchok J, et al. Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs). Ejc Supplements. 2009; 7:580.